Insulet Key Executives
This section highlights Insulet's key executives, including their titles and compensation details.
Find Contacts at Insulet
(Showing 0 of )
Insulet Earnings
This section highlights Insulet's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-20 | $1.00 | $1.15 |
| Read Transcript | Q3 | 2024 | 2024-11-07 | $0.76 | $0.90 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | $0.56 | $0.55 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $0.39 | $0.73 |
| Read Transcript | Q4 | 2023 | 2024-02-22 | $0.66 | $1.40 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $0.40 | $0.71 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $0.26 | $0.38 |
| Read Transcript | Q1 | 2023 | 2023-05-04 | $0.09 | $0.23 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
$260.71
Stock Price
$18.31B
Market Cap
3.90K
Employees
Acton, MA
Location
Financial Statements
Access annual & quarterly financial statements for Insulet, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.07B | $1.70B | $1.31B | $1.10B | $904.40M |
| Cost of Revenue | $625.90M | $537.20M | $499.70M | $346.70M | $322.10M |
| Gross Profit | $1.45B | $1.16B | $805.60M | $752.10M | $582.30M |
| Gross Profit Ratio | 69.79% | 68.35% | 61.72% | 68.45% | 64.39% |
| Research and Development Expenses | $219.60M | $205.00M | $180.20M | $160.10M | $146.80M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $917.20M | $734.90M | $587.80M | $466.00M | $384.00M |
| Other Expenses | $- | $- | $-1.10M | $-1.90M | $3.30M |
| Operating Expenses | $1.14B | $939.90M | $768.00M | $626.10M | $530.80M |
| Cost and Expenses | $1.76B | $1.48B | $1.27B | $972.80M | $852.90M |
| Interest Income | $39.50M | $28.60M | $9.80M | $500.00K | $3.00M |
| Interest Expense | $42.70M | $36.20M | $26.70M | $61.20M | $45.10M |
| Depreciation and Amortization | $80.80M | $72.80M | $63.20M | $57.40M | $55.40M |
| EBITDA | $423.70M | $323.60M | $109.50M | $139.60M | $110.30M |
| EBITDA Ratio | 20.45% | 19.07% | 8.39% | 12.70% | 12.20% |
| Operating Income | $308.90M | $220.00M | $-26.70M | $66.70M | $-600.00K |
| Operating Income Ratio | 14.91% | 12.96% | -2.05% | 6.07% | -0.07% |
| Total Other Income Expenses Net | $-8.70M | $-5.40M | $-27.80M | $-105.50M | $-41.80M |
| Income Before Tax | $300.20M | $214.60M | $9.80M | $20.50M | $9.70M |
| Income Before Tax Ratio | 14.49% | 12.65% | 0.75% | 1.87% | 1.07% |
| Income Tax Expense | $-118.10M | $8.30M | $5.20M | $3.70M | $2.90M |
| Net Income | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M |
| Net Income Ratio | 20.19% | 12.16% | 0.35% | 1.53% | 0.75% |
| EPS | $5.97 | $2.96 | $0.07 | $0.25 | $0.11 |
| EPS Diluted | $5.66 | $2.80 | $0.07 | $0.25 | $0.10 |
| Weighted Average Shares Outstanding | 70.08M | 69.75M | 69.38M | 67.70M | 64.73M |
| Weighted Average Shares Outstanding Diluted | 73.89M | 73.63M | 69.91M | 68.58M | 65.95M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $597.50M | $372.60M | $488.50M | $441.70M | $509.80M | $432.70M | $396.50M | $358.10M | $369.70M | $340.80M | $299.40M | $295.40M | $307.70M | $275.60M | $263.20M | $252.30M | $246.10M | $234.00M | $226.30M | $198.00M |
| Cost of Revenue | $166.60M | $-4.50M | $154.30M | $131.80M | $148.60M | $139.40M | $131.60M | $117.60M | $152.40M | $152.50M | $109.10M | $85.70M | $94.50M | $86.90M | $80.50M | $84.80M | $85.00M | $82.20M | $83.80M | $71.10M |
| Gross Profit | $430.90M | $377.10M | $334.20M | $309.90M | $361.20M | $293.30M | $264.90M | $240.50M | $217.30M | $188.30M | $190.30M | $209.70M | $213.20M | $188.70M | $182.70M | $167.50M | $161.10M | $151.80M | $142.50M | $126.90M |
| Gross Profit Ratio | 72.12% | 101.21% | 68.41% | 70.16% | 70.85% | 67.78% | 66.81% | 67.16% | 58.78% | 55.25% | 63.56% | 70.99% | 69.29% | 68.47% | 69.41% | 66.39% | 65.46% | 64.87% | 62.97% | 64.09% |
| Research and Development Expenses | $60.60M | $54.90M | $53.90M | $50.20M | $42.00M | $57.80M | $55.10M | $50.10M | $49.50M | $45.00M | $42.60M | $43.10M | $41.80M | $37.50M | $40.10M | $40.70M | $38.30M | $38.80M | $34.20M | $35.50M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $261.00M | $234.10M | $220.00M | $197.30M | $212.80M | $180.70M | $178.70M | $162.70M | $144.30M | $140.40M | $174.40M | $128.70M | $121.70M | $117.50M | $116.30M | $110.50M | $130.10M | $89.20M | $80.80M | $83.90M |
| Other Expenses | $- | $- | $-5.70M | $-5.50M | $-300.00K | $700.00K | $-200.00K | $- | $1.50M | $-1.80M | $-1.10M | $300.00K | $-400.00K | $-700.00K | $1.80M | $-2.60M | $1.30M | $1.00M | $1.00M | $- |
| Operating Expenses | $321.60M | $289.00M | $279.60M | $253.00M | $254.80M | $238.50M | $233.80M | $212.80M | $193.80M | $185.40M | $217.00M | $171.80M | $163.50M | $155.00M | $156.40M | $151.20M | $168.40M | $128.00M | $115.00M | $119.40M |
| Cost and Expenses | $488.20M | $284.50M | $433.90M | $384.80M | $403.40M | $377.90M | $365.40M | $330.40M | $346.20M | $337.90M | $326.10M | $257.50M | $258.00M | $241.90M | $236.90M | $236.00M | $253.40M | $210.20M | $198.80M | $190.50M |
| Interest Income | $10.30M | $10.50M | $9.30M | $9.40M | $6.20M | $8.60M | $7.30M | $6.50M | $6.50M | $2.40M | $800.00K | $100.00K | $- | $100.00K | $200.00K | $200.00K | $300.00K | $500.00K | $700.00K | $1.50M |
| Interest Expense | $8.70M | $12.30M | $11.00M | $10.70M | $6.70M | $1.80M | $2.40M | $9.40M | $2.70M | $6.80M | $8.30M | $8.90M | $15.10M | $16.30M | $16.40M | $13.40M | $12.50M | $11.40M | $11.10M | $10.10M |
| Depreciation and Amortization | $21.50M | $21.30M | $19.20M | $18.80M | $18.80M | $18.70M | $18.10M | $17.20M | $16.20M | $12.40M | $17.50M | $17.10M | $14.90M | $14.50M | $15.20M | $12.80M | $25.70M | $10.90M | $9.90M | $8.90M |
| EBITDA | $141.50M | $116.50M | $81.30M | $103.90M | $127.10M | $82.80M | $56.30M | $51.20M | $47.70M | $15.90M | $-9.50M | $55.40M | $63.40M | $46.10M | $3.40M | $26.70M | $20.00M | $36.20M | $39.10M | $17.90M |
| EBITDA Ratio | 23.68% | 31.27% | 16.64% | 23.52% | 24.93% | 19.14% | 14.20% | 14.30% | 12.90% | 4.67% | -3.17% | 18.75% | 20.60% | 16.73% | 1.29% | 10.58% | 8.13% | 15.47% | 17.28% | 9.04% |
| Operating Income | $109.30M | $88.10M | $54.60M | $56.90M | $123.80M | $54.80M | $31.10M | $27.70M | $8.80M | $-14.80M | $-26.70M | $22.90M | $49.70M | $33.70M | $26.30M | $16.30M | $-7.30M | $23.80M | $27.50M | $7.50M |
| Operating Income Ratio | 18.29% | 23.64% | 11.18% | 12.88% | 24.28% | 12.66% | 7.84% | 7.74% | 2.38% | -4.34% | -8.92% | 7.75% | 16.15% | 12.23% | 9.99% | 6.46% | -2.97% | 10.17% | 12.15% | 3.79% |
| Total Other Income Expenses Net | $2.00M | $-5.20M | $-3.50M | $-2.00M | $1.40M | $-1.10M | $-2.60M | $-3.10M | $-1.20M | $-8.60M | $-9.40M | $-8.60M | $-16.30M | $-18.50M | $-54.70M | $-16.00M | $-11.20M | $-10.40M | $-10.10M | $-10.10M |
| Income Before Tax | $111.30M | $82.90M | $51.10M | $54.90M | $107.80M | $53.70M | $28.50M | $24.60M | $22.30M | $-5.70M | $-36.10M | $29.30M | $33.40M | $15.20M | $-28.40M | $300.00K | $-18.50M | $13.40M | $17.40M | $-2.60M |
| Income Before Tax Ratio | 18.63% | 22.25% | 10.46% | 12.43% | 21.15% | 12.41% | 7.19% | 6.87% | 6.03% | -1.67% | -12.06% | 9.92% | 10.85% | 5.52% | -10.79% | 0.12% | -7.52% | 5.73% | 7.69% | -1.31% |
| Income Tax Expense | $10.60M | $5.40M | $-137.50M | $3.40M | $-12.10M | $1.80M | $1.20M | $800.00K | $5.30M | $-500.00K | $-1.10M | $1.50M | $4.20M | $2.60M | $-3.40M | $300.00K | $-1.40M | $1.80M | $3.00M | $-500.00K |
| Net Income | $100.70M | $77.50M | $188.60M | $51.50M | $103.30M | $51.90M | $27.30M | $23.80M | $17.00M | $-5.20M | $-35.00M | $27.80M | $29.20M | $12.60M | $-25.00M | $600.00K | $-17.10M | $11.60M | $14.40M | $-2.10M |
| Net Income Ratio | 16.85% | 20.80% | 38.61% | 11.66% | 20.26% | 11.99% | 6.89% | 6.65% | 4.60% | -1.53% | -11.69% | 9.41% | 9.49% | 4.57% | -9.50% | 0.24% | -6.95% | 4.96% | 6.36% | -1.06% |
| EPS | $1.54 | $1.14 | $2.73 | $0.74 | $1.48 | $0.74 | $0.39 | $0.34 | $0.24 | $-0.07 | $-0.50 | $0.40 | $0.42 | $0.18 | $-0.37 | $0.01 | $-0.26 | $0.18 | $0.22 | $-0.03 |
| EPS Diluted | $1.46 | $1.08 | $2.59 | $0.73 | $1.48 | $0.70 | $0.39 | $0.34 | $0.24 | $-0.07 | $-0.50 | $0.40 | $0.42 | $0.18 | $-0.37 | $0.01 | $-0.26 | $0.17 | $0.22 | $-0.03 |
| Weighted Average Shares Outstanding | 70.16M | 70.12M | 70.06M | 69.96M | 69.86M | 69.82M | 69.74M | 70.10M | 69.47M | 69.42M | 69.36M | 69.25M | 69.07M | 68.87M | 66.70M | 66.11M | 65.94M | 65.72M | 64.37M | 62.88M |
| Weighted Average Shares Outstanding Diluted | 74.08M | 73.95M | 73.80M | 73.74M | 69.86M | 73.62M | 70.14M | 70.10M | 70.02M | 69.42M | 69.36M | 69.86M | 69.81M | 69.62M | 66.70M | 66.11M | 65.94M | 66.83M | 65.58M | 62.88M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $953.40M | $704.20M | $674.70M | $791.60M | $947.60M |
| Short Term Investments | $- | $26.90M | $50.80M | $- | $40.40M |
| Cash and Short Term Investments | $953.40M | $704.20M | $674.70M | $791.60M | $947.60M |
| Net Receivables | $365.50M | $359.70M | $205.60M | $161.00M | $83.80M |
| Inventory | $430.40M | $402.60M | $346.80M | $303.20M | $154.30M |
| Other Current Assets | $142.00M | $116.40M | $86.90M | $75.60M | $63.00M |
| Total Current Assets | $1.89B | $1.58B | $1.31B | $1.33B | $1.25B |
| Property Plant Equipment Net | $723.10M | $692.80M | $599.90M | $536.50M | $478.70M |
| Goodwill | $51.50M | $51.70M | $51.70M | $39.80M | $39.80M |
| Intangible Assets | $98.50M | $98.70M | $75.50M | $36.60M | $28.70M |
| Goodwill and Intangible Assets | $150.00M | $150.40M | $127.20M | $76.40M | $68.50M |
| Long Term Investments | $- | $26.60M | $15.00M | $19.30M | $14.80M |
| Tax Assets | $141.80M | $- | $-15.00M | $-19.30M | $-14.80M |
| Other Non-Current Assets | $181.50M | $135.50M | $210.00M | $106.10M | $77.00M |
| Total Non-Current Assets | $1.20B | $1.01B | $937.10M | $719.00M | $624.20M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B |
| Account Payables | $19.80M | $19.20M | $30.80M | $37.70M | $54.10M |
| Short Term Debt | $83.80M | $49.40M | $27.50M | $25.10M | $15.60M |
| Tax Payables | $- | $- | $- | $- | $5.00M |
| Deferred Revenue | $- | $- | $16.10M | $3.50M | $5.40M |
| Other Current Liabilities | $424.80M | $382.60M | $306.40M | $166.00M | $133.10M |
| Total Current Liabilities | $528.40M | $451.20M | $364.70M | $228.80M | $207.80M |
| Long Term Debt | $- | $1.37B | $1.40B | $1.25B | $1.06B |
| Deferred Revenue Non-Current | $- | $- | $1.60M | $1.50M | $1.00M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-1.60M | $-1.50M | $-1.00M |
| Other Non-Current Liabilities | $1.35B | $37.90M | $8.30M | $14.90M | $5.80M |
| Total Non-Current Liabilities | $1.35B | $1.40B | $1.41B | $1.26B | $1.06B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.88B | $1.86B | $1.77B | $1.49B | $1.27B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
| Retained Earnings | $40.30M | $-378.00M | $-584.30M | $-649.50M | $-666.30M |
| Accumulated Other Comprehensive Income Loss | $-13.20M | $8.00M | $20.00M | $-2.20M | $5.50M |
| Other Total Stockholders Equity | $1.18B | $1.10B | $1.04B | $1.21B | $1.26B |
| Total Stockholders Equity | $1.21B | $732.70M | $476.40M | $556.30M | $603.60M |
| Total Equity | $1.21B | $732.70M | $476.40M | $556.30M | $603.60M |
| Total Liabilities and Stockholders Equity | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B |
| Total Investments | $- | $53.50M | $65.80M | $19.30M | $40.40M |
| Total Debt | $83.80M | $1.42B | $1.40B | $1.25B | $1.04B |
| Net Debt | $-869.60M | $711.60M | $727.10M | $457.20M | $96.10M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $953.40M | $902.60M | $715.50M | $696.90M | $650.70M | $685.40M | $660.10M | $620.70M | $674.70M | $722.00M | $708.60M | $709.60M | $791.60M | $857.10M | $872.10M | $850.20M | $947.60M | $896.70M | $844.40M | $321.60M |
| Short Term Investments | $- | $- | $105.50M | $54.30M | $53.50M | $104.70M | $103.30M | $- | $50.80M | $50.40M | $50.00M | $- | $- | $500.00K | $17.50M | $29.50M | $40.40M | $58.60M | $65.30M | $120.20M |
| Cash and Short Term Investments | $953.40M | $902.60M | $821.00M | $751.20M | $704.20M | $685.40M | $660.10M | $620.70M | $674.70M | $722.00M | $708.60M | $709.60M | $791.60M | $857.10M | $872.10M | $850.20M | $947.60M | $896.70M | $844.40M | $321.60M |
| Net Receivables | $365.50M | $261.70M | $348.60M | $320.50M | $359.70M | $270.30M | $250.50M | $217.20M | $205.60M | $201.40M | $206.60M | $189.30M | $161.00M | $114.30M | $100.30M | $97.90M | $83.80M | $85.40M | $78.00M | $80.10M |
| Inventory | $430.40M | $444.90M | $430.90M | $430.60M | $402.60M | $410.80M | $411.30M | $386.10M | $346.80M | $327.60M | $320.40M | $314.80M | $303.20M | $259.00M | $197.80M | $170.10M | $154.30M | $124.90M | $103.70M | $95.70M |
| Other Current Assets | $142.00M | $251.70M | $130.60M | $99.30M | $116.40M | $104.60M | $99.60M | $106.00M | $86.90M | $78.60M | $74.70M | $72.80M | $75.60M | $153.00M | $165.40M | $76.40M | $63.00M | $106.80M | $119.20M | $46.80M |
| Total Current Assets | $1.89B | $1.86B | $1.73B | $1.60B | $1.57B | $1.47B | $1.42B | $1.33B | $1.31B | $1.33B | $1.31B | $1.29B | $1.33B | $1.31B | $1.25B | $1.19B | $1.25B | $1.16B | $1.09B | $541.30M |
| Property Plant Equipment Net | $723.10M | $702.90M | $677.90M | $667.70M | $692.80M | $649.20M | $601.50M | $596.60M | $599.90M | $553.10M | $535.80M | $538.20M | $536.50M | $515.40M | $505.50M | $497.90M | $478.70M | $449.20M | $423.20M | $412.40M |
| Goodwill | $51.50M | $51.70M | $51.70M | $51.70M | $51.70M | $51.70M | $51.70M | $51.70M | $51.70M | $51.60M | $51.80M | $51.80M | $39.80M | $39.80M | $39.90M | $39.80M | $39.80M | $39.70M | $39.60M | $39.60M |
| Intangible Assets | $98.50M | $99.60M | $98.50M | $98.50M | $98.70M | $99.50M | $99.50M | $100.20M | $75.50M | $53.70M | $55.10M | $52.80M | $36.60M | $37.20M | $33.40M | $29.70M | $28.70M | $10.40M | $10.90M | $12.40M |
| Goodwill and Intangible Assets | $150.00M | $151.30M | $150.20M | $150.20M | $150.40M | $151.20M | $151.20M | $151.90M | $127.20M | $105.30M | $106.90M | $104.60M | $76.40M | $77.00M | $73.30M | $69.50M | $68.50M | $50.10M | $50.50M | $52.00M |
| Long Term Investments | $- | $- | $- | $37.60M | $26.60M | $31.40M | $34.00M | $- | $15.00M | $15.10M | $15.20M | $15.30M | $19.30M | $14.80M | $14.80M | $14.80M | $- | $500.00K | $23.50M | $60.80M |
| Tax Assets | $141.80M | $144.40M | $141.10M | $-37.60M | $-26.60M | $-31.40M | $-34.00M | $- | $-15.00M | $-15.10M | $-15.20M | $-15.30M | $-19.30M | $-14.80M | $-14.80M | $-14.80M | $- | $- | $- | $- |
| Other Non-Current Assets | $181.50M | $165.90M | $181.30M | $204.50M | $178.70M | $196.20M | $211.60M | $210.60M | $210.00M | $178.70M | $161.90M | $125.70M | $86.80M | $84.80M | $77.20M | $66.10M | $77.00M | $50.40M | $43.80M | $41.70M |
| Total Non-Current Assets | $1.20B | $1.16B | $1.15B | $1.02B | $1.02B | $996.60M | $964.30M | $959.10M | $937.10M | $837.10M | $804.60M | $783.80M | $719.00M | $692.00M | $670.80M | $648.30M | $624.20M | $550.20M | $541.00M | $566.90M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.09B | $3.03B | $2.88B | $2.62B | $2.59B | $2.47B | $2.39B | $2.29B | $2.25B | $2.17B | $2.11B | $2.07B | $2.05B | $2.00B | $1.92B | $1.84B | $1.87B | $1.71B | $1.63B | $1.11B |
| Account Payables | $19.80M | $40.30M | $76.80M | $75.90M | $19.20M | $77.80M | $107.50M | $85.90M | $30.80M | $62.10M | $57.20M | $52.20M | $37.70M | $58.00M | $49.30M | $59.10M | $54.10M | $57.00M | $35.60M | $36.40M |
| Short Term Debt | $83.80M | $42.00M | $37.90M | $38.90M | $52.90M | $49.80M | $29.20M | $27.80M | $27.50M | $26.90M | $26.30M | $25.70M | $25.10M | $28.90M | $20.90M | $15.70M | $15.60M | $4.60M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.40M | $5.00M | $5.90M | $5.00M | $4.90M | $3.90M | $2.70M |
| Deferred Revenue | $- | $- | $21.90M | $18.20M | $15.40M | $13.80M | $19.40M | $- | $16.10M | $3.50M | $3.30M | $1.30M | $3.50M | $4.40M | $5.00M | $5.90M | $5.00M | $4.30M | $5.00M | $- |
| Other Current Liabilities | $424.80M | $423.90M | $349.40M | $299.40M | $379.10M | $323.80M | $288.30M | $269.60M | $306.40M | $245.20M | $195.80M | $137.10M | $166.00M | $137.30M | $138.10M | $104.80M | $133.10M | $104.40M | $89.90M | $91.30M |
| Total Current Liabilities | $528.40M | $506.20M | $486.00M | $432.40M | $451.20M | $451.40M | $425.00M | $383.30M | $364.70M | $334.20M | $279.30M | $215.00M | $228.80M | $228.60M | $213.30M | $185.50M | $207.80M | $175.20M | $134.40M | $130.40M |
| Long Term Debt | $- | $1.36B | $1.36B | $1.36B | $1.40B | $1.37B | $1.37B | $1.37B | $1.40B | $1.38B | $1.39B | $1.39B | $1.25B | $1.26B | $1.24B | $1.05B | $1.06B | $921.50M | $910.20M | $899.00M |
| Deferred Revenue Non-Current | $- | $- | $2.00M | $2.00M | $1.90M | $1.80M | $1.80M | $- | $1.60M | $1.50M | $1.60M | $1.50M | $1.50M | $1.50M | $1.40M | $1.20M | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $29.50M | $-1.80M | $-1.80M | $- | $-1.60M | $-1.50M | $-1.60M | $-1.50M | $-1.50M | $-1.50M | $-1.40M | $-1.20M | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.35B | $44.90M | $35.30M | $36.30M | $8.40M | $38.20M | $38.30M | $34.20M | $8.30M | $24.20M | $26.80M | $17.00M | $14.90M | $15.40M | $16.10M | $17.70M | $5.80M | $18.90M | $18.80M | $19.80M |
| Total Non-Current Liabilities | $1.35B | $1.40B | $1.40B | $1.40B | $1.40B | $1.41B | $1.41B | $1.40B | $1.41B | $1.40B | $1.41B | $1.41B | $1.26B | $1.27B | $1.25B | $1.07B | $1.06B | $940.40M | $929.00M | $918.80M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.88B | $1.91B | $1.88B | $1.83B | $1.86B | $1.86B | $1.83B | $1.79B | $1.77B | $1.74B | $1.69B | $1.62B | $1.49B | $1.50B | $1.46B | $1.25B | $1.27B | $1.12B | $1.06B | $1.05B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
| Retained Earnings | $- | $-60.40M | $-137.90M | $-326.50M | $-378.00M | $-481.30M | $-533.20M | $-560.50M | $-584.30M | $-601.30M | $-596.10M | $-561.10M | $-649.50M | $-678.70M | $-691.30M | $-666.30M | $-666.30M | $-649.20M | $-660.80M | $-675.20M |
| Accumulated Other Comprehensive Income Loss | $-13.20M | $19.70M | $-4.40M | $-500.00K | $8.00M | $7.60M | $16.30M | $15.90M | $20.00M | $6.80M | $7.20M | $12.20M | $-2.20M | $-3.40M | $700.00K | $3.20M | $5.50M | $-600.00K | $-3.60M | $-3.80M |
| Other Total Stockholders Equity | $1.22B | $1.16B | $1.14B | $1.12B | $1.10B | $1.08B | $1.07B | $1.05B | $1.04B | $1.02B | $1.01B | $995.50M | $1.21B | $1.18B | $1.15B | $1.25B | $1.26B | $1.24B | $1.23B | $737.90M |
| Total Stockholders Equity | $1.21B | $1.12B | $998.40M | $790.70M | $732.70M | $607.50M | $553.90M | $502.80M | $476.40M | $428.00M | $422.40M | $446.70M | $556.30M | $497.90M | $459.10M | $585.30M | $603.60M | $595.00M | $563.30M | $59.00M |
| Total Equity | $1.21B | $1.12B | $998.40M | $790.70M | $732.70M | $607.50M | $553.90M | $502.80M | $476.40M | $428.00M | $422.40M | $446.70M | $556.30M | $497.90M | $459.10M | $585.30M | $603.60M | $595.00M | $563.30M | $59.00M |
| Total Liabilities and Stockholders Equity | $3.09B | $3.03B | $2.88B | $2.62B | $2.59B | $2.47B | $2.39B | $2.29B | $2.25B | $2.17B | $2.11B | $2.07B | $2.05B | $2.00B | $1.92B | $1.84B | $1.87B | $1.71B | $1.63B | $1.11B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.09B | $3.03B | $2.88B | $2.62B | $2.59B | $2.47B | $2.39B | $2.29B | $2.25B | $2.17B | $2.11B | $2.07B | $2.05B | $2.00B | $1.92B | $1.84B | $1.87B | $1.71B | $1.63B | $1.11B |
| Total Investments | $- | $- | $105.50M | $54.30M | $53.50M | $104.70M | $103.30M | $- | $65.80M | $65.50M | $65.20M | $15.30M | $19.30M | $500.00K | $17.50M | $29.50M | $40.40M | $59.10M | $88.80M | $181.00M |
| Total Debt | $83.80M | $1.40B | $1.40B | $1.40B | $1.45B | $1.42B | $1.40B | $1.40B | $1.40B | $1.41B | $1.41B | $1.42B | $1.25B | $1.26B | $1.24B | $1.05B | $1.04B | $921.50M | $910.20M | $899.00M |
| Net Debt | $-869.60M | $495.70M | $682.30M | $704.60M | $798.10M | $735.00M | $737.70M | $775.90M | $727.10M | $684.70M | $702.90M | $706.60M | $457.20M | $399.90M | $363.10M | $201.40M | $96.10M | $24.80M | $65.80M | $577.40M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M |
| Depreciation and Amortization | $80.80M | $72.80M | $63.20M | $57.40M | $55.40M |
| Deferred Income Tax | $-136.90M | $- | $- | $45.50M | $3.30M |
| Stock Based Compensation | $69.30M | $48.30M | $40.90M | $34.40M | $35.90M |
| Change in Working Capital | $- | $-190.60M | $-2.50M | $-263.60M | $-63.40M |
| Accounts Receivables | $-16.90M | $-154.20M | $-51.80M | $-71.30M | $-15.60M |
| Inventory | $-32.40M | $-53.60M | $-49.10M | $-154.40M | $-50.50M |
| Accounts Payables | $2.20M | $-11.00M | $-2.40M | $-15.60M | $7.10M |
| Other Working Capital | $- | $28.20M | $100.80M | $-22.30M | $-4.40M |
| Other Non Cash Items | $-1.20M | $8.90M | $12.80M | $41.40M | $46.00M |
| Net Cash Provided by Operating Activities | $430.30M | $145.70M | $119.00M | $-68.10M | $84.00M |
| Investments in Property Plant and Equipment | $-124.90M | $-75.60M | $-157.30M | $-122.70M | $-166.50M |
| Acquisitions Net | $- | $-3.00M | $-26.00M | $- | $166.50M |
| Purchases of Investments | $- | $-7.20M | $-7.80M | $- | $-37.90M |
| Sales Maturities of Investments | $- | $- | $40.00M | $40.00M | $218.40M |
| Other Investing Activities | $-21.30M | $-33.60M | $-40.00M | $29.20M | $-166.50M |
| Net Cash Used for Investing Activities | $-146.20M | $-119.40M | $-191.10M | $-82.70M | $14.00M |
| Debt Repayment | $-40.60M | $-27.00M | $-39.80M | $49.40M | $126.60M |
| Common Stock Issued | $- | $- | $16.30M | $23.50M | $477.50M |
| Common Stock Repurchased | $11.90M | $10.60M | $-16.80M | $-28.20M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $12.50M | $-13.50M | $-500.00K | $-8.70M | $1.40M |
| Net Cash Used Provided by Financing Activities | $-28.10M | $-13.60M | $-40.30M | $40.70M | $605.50M |
| Effect of Forex Changes on Cash | $-6.80M | $1.80M | $-4.30M | $-5.50M | $4.80M |
| Net Change in Cash | $249.20M | $14.50M | $-116.70M | $-115.60M | $708.30M |
| Cash at End of Period | $953.40M | $704.20M | $689.70M | $806.40M | $922.00M |
| Cash at Beginning of Period | $704.20M | $689.70M | $806.40M | $922.00M | $213.70M |
| Operating Cash Flow | $430.30M | $145.70M | $119.00M | $-68.10M | $84.00M |
| Capital Expenditure | $-124.90M | $-75.60M | $-157.30M | $-122.70M | $-166.50M |
| Free Cash Flow | $305.40M | $36.50M | $-38.30M | $-190.80M | $-82.50M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $100.70M | $77.50M | $188.60M | $51.50M | $103.30M | $51.90M | $27.30M | $23.80M | $17.00M | $-5.20M | $-35.00M | $27.80M | $29.20M | $12.60M | $-25.00M | $- | $-17.10M | $11.60M | $14.40M | $-2.10M |
| Depreciation and Amortization | $21.50M | $21.30M | $19.20M | $18.80M | $18.80M | $18.70M | $18.10M | $17.20M | $16.20M | $15.90M | $15.80M | $15.30M | $14.90M | $14.50M | $15.20M | $12.80M | $25.70M | $10.90M | $9.90M | $8.90M |
| Deferred Income Tax | $3.90M | $-1.60M | $-139.20M | $- | $-15.30M | $14.10M | $1.20M | $- | $- | $- | $- | $- | $1.10M | $2.20M | $40.30M | $- | $200.00K | $500.00K | $2.00M | $600.00K |
| Stock Based Compensation | $20.00M | $18.10M | $17.00M | $14.20M | $12.60M | $10.50M | $13.10M | $12.10M | $11.20M | $9.00M | $11.20M | $9.50M | $8.60M | $8.20M | $9.00M | $8.60M | $15.60M | $6.60M | $5.80M | $7.90M |
| Change in Working Capital | $700.00K | $-5.10M | $5.30M | $-200.00K | $-91.90M | $-25.60M | $-17.10M | $-56.00M | $2.00M | $34.20M | $29.30M | $-68.00M | $-88.60M | $-70.80M | $-31.90M | $-72.30M | $-37.50M | $21.00M | $-16.10M | $-30.80M |
| Accounts Receivables | $4.50M | $-29.20M | $-27.90M | $36.60M | $-86.90M | $-22.00M | $-33.20M | $-12.10M | $-1.00M | $600.00K | $-21.40M | $-30.00M | $-35.80M | $-16.00M | $-2.20M | $-17.30M | $4.30M | $-6.10M | $800.00K | $-14.60M |
| Inventory | $6.20M | $-8.30M | $-700.00K | $-29.60M | $11.70M | $-2.60M | $-24.50M | $-38.20M | $-14.60M | $-10.50M | $-11.00M | $-13.00M | $-46.30M | $-63.10M | $-27.10M | $-17.90M | $-27.60M | $-20.10M | $-7.60M | $4.80M |
| Accounts Payables | $-17.80M | $-36.40M | $900.00K | $55.50M | $-52.50M | $-33.00M | $23.00M | $51.50M | $-25.70M | $3.20M | $5.40M | $14.70M | $-21.60M | $10.40M | $-9.40M | $5.00M | $7.10M | $11.60M | $-8.20M | $-20.40M |
| Other Working Capital | $7.80M | $68.80M | $33.00M | $-62.70M | $35.80M | $32.00M | $17.60M | $-57.20M | $43.30M | $40.90M | $56.30M | $-39.70M | $15.10M | $-2.10M | $6.80M | $-42.10M | $-21.30M | $47.20M | $-1.10M | $-600.00K |
| Other Non Cash Items | $900.00K | $-11.70M | $5.60M | $-7.40M | $17.40M | $-13.60M | $1.40M | $3.40M | $4.30M | $2.80M | $4.00M | $1.70M | $9.30M | $7.50M | $10.70M | $15.80M | $12.10M | $11.60M | $10.40M | $11.90M |
| Net Cash Provided by Operating Activities | $147.70M | $98.50M | $96.50M | $87.60M | $44.90M | $56.00M | $44.00M | $500.00K | $50.70M | $56.70M | $25.30M | $-13.70M | $-25.50M | $-25.80M | $18.30M | $-35.10M | $-1.00M | $62.20M | $26.40M | $-3.60M |
| Investments in Property Plant and Equipment | $-56.00M | $-22.40M | $-24.90M | $-24.00M | $-31.60M | $-22.40M | $-18.10M | $-37.10M | $-88.40M | $-33.90M | $-19.10M | $-15.90M | $-36.90M | $-29.20M | $-23.20M | $-33.40M | $-69.70M | $-44.60M | $-24.80M | $-27.40M |
| Acquisitions Net | $- | $- | $- | $- | $33.60M | $- | $-3.00M | $-3.00M | $26.00M | $- | $- | $-26.00M | $- | $- | $- | $- | $- | $- | $24.80M | $26.90M |
| Purchases of Investments | $-12.00M | $- | $- | $- | $7.20M | $-200.00K | $-5.00M | $-2.00M | $7.80M | $- | $-2.80M | $-5.00M | $- | $- | $- | $- | $- | $- | $100.00K | $-38.00M |
| Sales Maturities of Investments | $- | $- | $- | $- | $-28.60M | $- | $- | $- | $40.00M | $- | $- | $34.10M | $500.00K | $17.00M | $11.80M | $10.70M | $18.40M | $29.30M | $91.90M | $78.80M |
| Other Investing Activities | $- | $-6.90M | $- | $-1.90M | $-12.20M | $-2.50M | $3.00M | $- | $-73.80M | $-2.80M | $-7.30M | $-34.10M | $-4.60M | $15.10M | $8.50M | $10.20M | $-18.50M | $29.20M | $-24.80M | $-26.90M |
| Net Cash Used for Investing Activities | $-68.00M | $-29.30M | $-24.90M | $-24.00M | $-31.60M | $-22.60M | $-23.10M | $-42.10M | $-88.40M | $-33.90M | $-21.90M | $-46.90M | $-36.40M | $-12.20M | $-11.40M | $-22.70M | $-51.30M | $-15.30M | $67.20M | $13.40M |
| Debt Repayment | $-26.70M | $7.90M | $-6.90M | $-14.90M | $-6.70M | $-6.80M | $-6.80M | $-6.70M | $-21.50M | $-6.10M | $-6.10M | $-6.10M | $-10.00M | $38.10M | $25.10M | $-3.80M | $128.30M | $- | $- | $- |
| Common Stock Issued | $- | $-12.90M | $7.10M | $5.80M | $9.00M | $100.00K | $11.80M | $- | $7.10M | $2.40M | $5.70M | $1.10M | $9.10M | $4.40M | $8.50M | $1.50M | $477.50M | $- | $- | $- |
| Common Stock Repurchased | $- | $11.00M | $- | $-5.00M | $-100.00K | $-200.00K | $-1.50M | $- | $-100.00K | $-200.00K | $-1.20M | $-15.30M | $-600.00K | $-300.00K | $-1.20M | $-26.10M | $-2.90M | $-100.00K | $-1.60M | $-25.20M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.80M | $-100.00K | $-1.10M | $800.00K | $8.90M | $-100.00K | $10.00M | $-5.40M | $7.00M | $2.20M | $4.50M | $-14.20M | $8.50M | $4.10M | $3.30M | $-24.60M | $1.80M | $10.50M | $483.90M | $-19.00M |
| Net Cash Used Provided by Financing Activities | $-20.90M | $7.80M | $-900.00K | $-14.10M | $2.20M | $-6.90M | $3.20M | $-12.10M | $-14.50M | $-3.90M | $-1.60M | $-20.30M | $-1.50M | $42.20M | $28.40M | $-28.40M | $130.10M | $10.50M | $483.90M | $-19.00M |
| Effect of Forex Changes on Cash | $-8.00M | $4.60M | $-900.00K | $-2.50M | $3.00M | $-1.20M | $100.00K | $-100.00K | $4.80M | $-5.60M | $-2.90M | $-600.00K | $-1.60M | $-2.20M | $-1.40M | $-300.00K | $6.10M | $1.60M | $200.00K | $-3.10M |
| Net Change in Cash | $50.80M | $187.10M | $18.60M | $46.20M | $70.00M | $25.30M | $24.20M | $-53.80M | $-47.40M | $13.30M | $-1.10M | $-81.50M | $-65.00M | $2.00M | $33.90M | $-86.50M | $83.90M | $59.00M | $577.70M | $-12.30M |
| Cash at End of Period | $953.40M | $902.60M | $715.50M | $696.90M | $650.70M | $685.40M | $660.10M | $635.90M | $689.70M | $737.10M | $723.80M | $724.90M | $806.40M | $871.40M | $869.40M | $835.50M | $922.00M | $838.10M | $779.10M | $201.40M |
| Cash at Beginning of Period | $902.60M | $715.50M | $696.90M | $650.70M | $580.70M | $660.10M | $635.90M | $689.70M | $737.10M | $723.80M | $724.90M | $806.40M | $871.40M | $869.40M | $835.50M | $922.00M | $838.10M | $779.10M | $201.40M | $213.70M |
| Operating Cash Flow | $147.70M | $98.50M | $96.50M | $87.60M | $44.90M | $56.00M | $44.00M | $500.00K | $50.70M | $56.70M | $25.30M | $-13.70M | $-25.50M | $-25.80M | $18.30M | $-35.10M | $-1.00M | $62.20M | $26.40M | $-3.60M |
| Capital Expenditure | $-56.00M | $-22.40M | $-24.90M | $-24.00M | $-31.60M | $-22.40M | $-18.10M | $-37.10M | $-88.40M | $-33.90M | $-19.10M | $-15.90M | $-36.90M | $-29.20M | $-23.20M | $-33.40M | $-69.70M | $-44.60M | $-24.80M | $-27.40M |
| Free Cash Flow | $91.70M | $76.10M | $71.60M | $63.60M | $13.30M | $33.60M | $25.90M | $-36.60M | $-37.70M | $22.80M | $6.20M | $-29.60M | $-62.40M | $-55.00M | $-4.90M | $-68.50M | $-70.70M | $17.60M | $1.60M | $-31.00M |
Insulet Dividends
Explore Insulet's dividend history, including dividend yield, payout ratio, and historical payments.
Insulet News
Read the latest news about Insulet, including recent articles, headlines, and updates.
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Rela.
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
ACTON, Mass.--(BUSINESS WIRE)--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections.
Insulet Announces Pricing of Senior Notes Due 2033
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless earlier redeemed or repurchased. The closing of the private placement is expected to occur on March 20, 2025, subject to customary closing conditions.
Insulet Announces Proposed Financing Transactions
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement. The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash fr.
Insulet Leans Bullish (Technical Analysis)
PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with the PPO line above zero indicating positive long-term momentum. Volume analysis shows neutral to slightly bullish accumulation by institutional investors, with recent high volume supporting bullish price action.
Insulet to Host Investor Day on June 5, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's lea.
Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Issie Kirby - Redburn Atlantic Patrick Wood - Morgan Stanley Macauley Kilbane - William Blair Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matt Taylor - Jefferies Phillip Dantoin - Piper Sandler Chris Pasquale - Nephron Research Joanne Wuensch - Citi Operator Good afternoon ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief.
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for.
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PODD.